{"entity":{"id":"nct05918133","kind":"trial","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","aka":[],"tldr":"A phase 1/2 trial of PM8002 in triple-negative breast cancer, run by Biotheus Inc., active and no longer recruiting.","summary":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC is a phase 1/2 interventional study registered as NCT05918133 by Biotheus Inc., with 42 participants enrolled, started 2022-07-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: PM8002 and nab-paclitaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05918133","url":"https://clinicaltrials.gov/study/NCT05918133"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002"],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05918133","phase":"1/2","setting":"A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer","sponsor":"Biotheus Inc.","enrolled":42,"outcomes":[]},"route":"/trials/nct05918133/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}